Clinical Trial

Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated June 6, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the safety and immunogenicity of two dose levels of the single dose Recombinant RSV vaccine(CHO cells), when administered intramuscularly (IM) in healthy adults aged 18 years and older.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-11; most recent amendment 2025-06-04.
Status change: Recruiting → Active, Not Recruiting 2025-06-04
Status change: Not Yet Recruiting → Recruiting 2024-11-13
Trial Details
NCT Number NCT06642558
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions Respiratory Syncytial Virus (RSV)
Enrollment 522 participants
Start Date 2024-11-13
Primary Completion 2025-06-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-06-06